Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999

Emerging Infectious Diseases

Volumn 8, Issue 5, 2002, Pages 473-478

  Livermore, David M ^a   James, Dorothy ^b   Reacher, Mark ^c   Graham, Catriona ^a   Nichols, Thomas ^c   Stephens, Peter ^c   Johnson, Alan P ^b   George, Robert C ^c  

^a CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA; PREVALENCE; PROTEUS MIRABILIS; UNITED KINGDOM;

EID: 0036096283     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0805.010204     Document Type: Article

References (19)

1. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid
2. The mode of action of 4-quinolones and possible mechanisms of resistance
3. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals
4. Quinolone resistance from a transferable plasmid
5. Bacteremia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: Trend analysis
6. Report of the Working Party on Sensitivity Testing of the British Society for Antimicrobial Chemotherapy. A guide to sensitive testing
7. Are routine sensitivity test data suitable for the surveillance of resistance? Resistance rates amongst Escherichia coli from blood and CSF from 1991-1997, as assessed by routine and centralized testing
8. Antibiotic resistance in Escherichia coli isolated from blood and cerebrospinal fluid: A 6-year study of isolates from patients in England and Wales
9. Multiresistant bacteria as a hospital epidemic problem
10. Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients
11. Molecular epidemiological analysis of quinolone-resistant Escherichia coli causing bacteremia in neutropenic patients with leukemia in Korea
12. Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts
13. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center
14. Changing epidemiology of infections in patients with neutropenia and cancer: Emphasis on gram-positive and resistant bacteria
15. Emergence and dissemination of quinolone-resistant Escherichia coli in the community
16. Emerging bacterial drug resistance in hospital practice
17. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin